To assess the clinical relevance of our observation, we re-visited RNA-seq data of patients with EGFR-mutant lung cancers derived from tumors biopsied prior to and after EGFR-TKI (osimertinib or erlotinib) treatment (6). This evidence concerns the gene EGFR and lung carcinoma.